Akmez Latona: Clauss vs PT-Derived Fibrinogen in Relation to Viscoelastic Clot Strength
Akmez Latona, Specialist Emergency Physician at Queensland Health, reposted from RPTH Journal on LinkedIn:
”Coagulation profiles in Queensland Health report two fibrinogen measures: Clauss and PT-derived.
A novel aspect we introduced is the comparison of Clauss and PT-derived fibrinogen with viscoelastic clot firmness (ROTEM FIBTEM A5) across different domains of coagulopathy.
The findings show these tests are not interchangeable in context of low clot firmness and inform recommendations for fibrinogen reporting in critical bleeding within laboratory workflows.
Thank you Emergency Medicine Foundation – Australasia (EMF) for funding this study!”
RPTH Journal shared on LinkedIn about a recent article by Akmez Latona et al, adding:
”Fibrinogen testing in critical bleeding: Clauss or PT-derived, does it matter?
Two common assays are used to measure Fibrinogen: the Clauss method (Fib-C), considered the laboratory gold standard, and the prothrombin time-derived assay (Fib-D), a faster and cheaper alternative.
But are they interchangeable?
A new study in RPTH Journal compared both methods against viscoelastic clot firmness (ROTEM FIBTEM-A5) across all Queensland Health hospitals, using over 2,200 paired results from 2019 to 2025.
Key findings:
- Fib-C correlated more strongly with FIBTEM-A5 than Fib-D
- Fib-C showed higher accuracy for detecting critically low clot firmness
- Fib-D systematically overestimated fibrinogen levels compared with Fib-C – in trauma, chronic liver disease, and overall
The clinical implication is clear: in critical bleeding, Fib-C better reflects true clot firmness, and routine Fib-D reporting may be misleading rather than helpful.”
Title: Diagnostic accuracy of Clauss and prothrombin time–derived fibrinogen against rotational thromboelastometry FIBTEM-A5
Authors: Akmez Latona, Kate Hill, Mark Rane, Alan Ho, Biswadev Mitra
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving
-
Nov 8, 2026, 14:02Gabriela Hobbs: Recognizing Outstanding Abstract Achievements-ASH 2026
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI